The specific biological activity of low-molecular weight heparin prompted using CY 216 in ophtalmological surgery for thrombo-embolic prevention. We report preliminary results on 31 patients (9 males, 22 females, mean age 74,4) treated from 06/86 to 12/86 with a daily 0,3 ml sub-cutaneous injection of CY 216 started 2 hours prior to surgery until day 7, or day 10 for 7 patients. Coagulation tests included TCa and anti-Xa activity. All patients were checked daily for ocular haemorrnagies and thrombo-embolic manifestations. Anaesthesia was general in 16 cases and local in 15. Surgery was performed on 21 cataracts (67 %), 8 retinal detachments (26 %), 2 glaucomas (6 %).No patient developped any clinical thrombo-embolism condition. In that particular surgery where frequent local haemorrhagic complications occur and delay the onset of heparinotherapy, CY 216 treatment exhibited 3 minor eyelids ecchymosis, 1 choroid hematoma and 5 subconjonctival suffusions, all transient and not impacting specific surgical results ; and all already known as possible mechanical vascular aggression independant of heparinotherapy. 2 hyphemas (6 %) also occured, for which CY 216 was discontinued, still not impacting surgical results, and without excessive hypocoagulation according to tests. These biological tests showed no adverse effects ; TCa never raised more than 6" above controls, and anti-Xa activity raised to 4 times pre-treatment values ; in 3 patients, high values did not induce any haemorrhagic complications, a very strong argument in favor of excellent tolerance of CY 216 therapy.At this stage of preliminary results, the tolerance of CY 216 concerning local haemorrhagic risk in eye surgery can be evaluated as near to excellent.
Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells
